secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2025-01-27T23:59:59+00:00
Accession:  0000914475-25-000006
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine restructures Takeda deal for osavampator; gets global rights ex-Japan
--------------------------------------------------------------------------------

- Neurocrine obtains exclusive worldwide development/commercialisation rights for osavampator except Japan, converts from profit-sharing to royalty-bearing license.
- Takeda reacquires exclusive rights in Japan; royalties payable by each party on net sales in other's territory.
- Tiered royalties to Takeda: mid-to-upper teens (US), low double-digits (ex-US) as % of net sales.
- Phase 3 program for major depressive disorder expected to start H1 2025 after successful End-of-Phase 2 FDA meeting.
- Amended agreement dated January 24, 2025; press release issued January 27, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447525000006/0000914475-25-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447525000006/nbix-20250124.htm
  HTML page:      https://secwatch.observer/filing/0000914475-25-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer